The US FDA has approved multiple NDAs and BLAs in Feb 2020, leading to treatments for patients and advances in health care The Center for Drug Evaluation and Research (CDER) […]readmore
Tags : Eagle
1. Epizyme Reports the US FDA Acceptance of NDA for Tazverik (tazemetostat) to Treat Follicular Lymphoma Published: Feb 14, 2020 | Tags: Epizyme, Reports, US, FDA, Acceptance, NDA, Tazverik, tazemetostat, Follicular […]readmore
Shots: The US FDA has approved Eagle’s Pemfexy, a branded alternative to Alimta and is expected to be available in the market from Feb 01, 2022 with a subsequent uncapped […]readmore
Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb Published: Jan 10, 2020 | Tags: Nektar Therapeutics, Signs, Clinical Trial, Collaboration, Bristol-Myers Squibb 2. Eli Lilly to Acquire Dermira for […]readmore
Shots: Tyme to receive $20M up front for 10M restricted shares of common stock at $2/share, up to $20M milestones based on meeting @1EPs as OS in TYME-88-Panc pivotal trial […]readmore
Shots: Eagle to receive royalties increased from 25% to 30% on sales of Bendeka in the US and will keep increasing by 1% until it reaches 32%, on every Oct […]readmore